

(10)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 074 306
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82401571.3

(22) Date of filing: 24.08.82

(51) Int. Cl.³: C 07 D 473/18
C 07 F 9/65, C 12 P 17/12
A 61 K 31/52
//C07C69/12, C07D319/06,
C07D317/24

(30) Priority: 26.08.81 US 296604

(43) Date of publication of application:
16.03.83 Bulletin 83/11

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065(US)

(72) Inventor: Ashton, Wallace T.
122 Sweet Briar Drive
Clark New Jersey 07066(US)

(72) Inventor: Karkas, John D.
404 W. 116th Street
New York New York 10027(US)

(72) Inventor: Field, Arthur K.
376 Meadowbrook Road
North Wales Pennsylvania 19454(US)

(72) Inventor: Tolman, Richard L.
29 Upper Warren Way
Warren New Jersey 07060(US)

(74) Representative: Martin, Jean-Jacques et al,
Cabinet REGIMBEAU 26, Avenue Kléber
F-75116 Paris(FR)

(54) Anti-viral guanine derivatives.

(57) 9-(1,3-dihydroxy-2-propoxymethyl)guanine and 9-(2,3-dihydroxy-1-propoxymethyl)guanine have been found to have potent anti-viral activity against herpes viruses. These compounds, their acyl derivatives, their phosphate derivatives and their pharmaceutically acceptable salts, pharmaceutical formulations containing these compounds, the treatment of viral infections with these compounds, methods of preparing these compounds, and novel intermediates useful in their preparation are all disclosed.

The compounds may be prepared by reaction of the appropriate acetoxymethyl ether with diacetylguanine, followed by deprotection. The acetoxymethyl ethers may be obtained by reaction of glycerol formal with acetic anhydride in the presence of a catalyst.

EP 0 074 306 A2

Best Available Copy

TITLE MODIFIED.
see front page.

- 1 -

16672IA

ANTI-VIRAL COMPOUNDS

BACKGROUND OF THE INVENTION

5 The use of purine derivatives as anti-viral compounds is known. For example, U.S. Patent 4,027,025 discloses 8-azapurine derivatives such as 9-(2-hydroxyethoxymethyl)-8-azaguanine and 9-(2-benzoyloxyethoxymethyl)-8-azaguanine as anti-viral compounds.

10 U.S. Patent 4,146,715 discloses 2-amido-9-(2-acyloxyethoxymethyl)hypoxanthines.

U.S. Patent 4,199,574 discloses that 9-(2-hydroxyethoxymethyl) and related derivatives of certain 6-, and 2,6-substituted purines have
15 anti-viral activity.

European patent application publication 0 049 072 discloses that 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl]guanine has anti-viral activity.

5 OBJECTS OF THE INVENTION

 It is an object of the present invention to provide novel, anti-viral compounds. Another object of the present invention is to provide novel compounds having enhanced anti-viral activity compared to known
10 anti-viral compounds. Yet another object is to provide compounds having potent anti-viral activity against herpes viruses. Still another object is to provide compounds having antimycoplasmal activity. A
15 further object of the present invention is to provide pharmaceutical formulations for the effective administration of the novel compounds of the invention. Still another object is to provide methods for the preparation of the novel compounds of the present invention. These and other objects of the
20 present invention will become apparent from the following description.

SUMMARY OF THE INVENTION

 9-(1,3-dihydroxy-2-propoxymethyl)guanine and
25 9-(2,3-dihydroxy-1-propoxymethyl)guanine have been found to have potent anti-viral activities. These compounds, their acyl derivatives, their phosphate derivatives and their pharmaceutically acceptable salts, pharmaceutical formulations containing these
30 compounds, the treatment of viral infections with these compounds, methods of preparing these compounds,

and novel intermediates useful in their preparation are all disclosed. In addition, the acyl derivatives have antimycoplasmal activity.

The compounds of the present invention may be prepared by reaction of the appropriate acetoxymethyl ether with diacetylguanine, followed by deprotection. The acetoxymethyl ethers may be obtained by reaction of glycerol formal with acetic anhydride in the presence of a catalyst.


BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows phosphorylation reaction velocity versus concentration curves; and

Figure 2 is a bar graph showing results of treating HSV-1 infected mice with acycloguanosine or the compound of formula II.

DETAILED DESCRIPTION


The present invention relates to anti-viral compounds and, more particularly, to 9-(2,3-dihydroxy-1-propoxymethyl)guanine of formula I and 9-(1,3-dihydroxy-2-propoxymethyl)guanine of formula II.



I

- 4 -

16672IA



II

5

10

In the compounds of formulas I and II, the hydrogen atom of either hydroxyl group may be replaced

15

by an acyl group of formula $\text{-}\overset{\text{O}}{\parallel}\text{C-R}_3$ wherein R_3 is a straight or branched chain alkyl group of 1-20 carbon atoms which may be saturated or mono- or poly-unsaturated, aryl, substituted aryl, heterocyclyl, aralkyl, alkoxyalkyl or aryloxyalkyl, or the hydrogen atom of either hydroxyl group may be substituted by a

20

phosphate group of the formula $\text{-}\overset{\text{O}}{\parallel}\text{P-OR}^4$ wherein OR^5

25

R^4 and R^5 are independently H, a pharmaceutically acceptable cation, straight or branched chain alkyl of 1-8 carbon atoms, aryl, aralkyl, phosphate or pyrophosphate.


30

Preferably the alkyl group is from 1-10 carbon atoms, the aryl group is phenyl, optionally substituted by halogen or alkyl of C_{1-4} , the heterocyclyl group is pyridyl, piperidyl, furyl, imidazolyl, tetrahydrofuryl or thienyl, the aralkyl group is phenyl substituted by C_{1-4} , in the alkoxy-alkyl group both the alkoxy and alkyl groups contain 1-4


16672IA

carbon atoms, the aryloxyalkyl group is phenoxy substituted by C₁₋₄, the pharmaceutically acceptable cation is sodium, potassium, ammonium, alkyl (C₁₋₄) substituted ammonium, magnesium/2, calcium/2, or aluminum/3.

The compounds of formulas I and II may be prepared starting from glycerol formal, a mixture of 1,3-dioxan-5-ol of the formula




wherein R is H and 1,3-dioxolane-4-methanol of the formula



wherein R is H, of which the compound of formula III is normally the predominant species. The ratio of compounds of formulas III and IV in glycerol formal has been determined to be 57:43 by H. Tibert, Fresenius' Z. Anal. Chem., 265, 328 (1973). This ratio may vary, however, for different preparations of glycerol formal. It is to be understood that mixtures containing various ratios of the compounds of formulas III and IV may be employed according to the present invention.


The glycerol formal (mixture of compounds of formulas III and IV) is preferably acylated, e.g. by reaction with an acylating agent such as acetic anhydride in the presence of pyridine, without
 5 separation of the individual compounds of formulas III and IV, to give the corresponding acyloxy derivatives wherein R is acyl. This mixture is separated, e.g. by high performance liquid chromatography (HPLC).

Treatment of the compound of formula III
 10 wherein R is Ac (acetyl) with acetic anhydride in the presence of a catalyst, e.g. ZnCl_2 , gives acetoxymethyl 2,3-diacetoxy-1-propyl ether of formula



15 This reaction is exothermic and takes place at about ambient temperature preferably in an inert atmosphere, e.g. N_2 .

The compound of formula V is then purified and reacted neat or in an inert solvent such as
 20 triglyme with diacetylguanine, prepared as described by Ishido et al., Bull. Chem. Soc. Japan, 37, 1389 (1964), of the formula




at elevated temperature under vacuum in the presence of an acidic catalyst, e.g. ethanesulfonic acid, to

- 7 -

16672IA

form 2-acetamido-9-(2,3-diacetoxy-1-propoxy-methyl)hypoxanthine VIII of the formula




as a viscous oil. The oil is taken up in a suitable solvent, e.g. ethyl acetate, and allowed to crystallize.

15 The compound of formula VIII is then deacetylated, e.g. by heating with aqueous methylamine under reflux preferably in an inert atmosphere, e.g. N₂, and then cooled to yield a solution containing the compound of formula I which is optionally treated with charcoal and filtered. Concentration of the filtrate gives a solid which is recrystallized from H₂O to give a crystalline product.

25 The compound of formula II may be obtained in similar fashion by reacting the compound of formula IV wherein R is Ac with acetic anhydride in the presence of a catalyst, e.g. ZnCl₂, to give acetoxymethyl 1,3-diacetoxy-2-propyl ether of the formula

30




- 8 -

16672IA

This reaction takes place under similar conditions as used to form compound V from compound III wherein R is Ac.

5 The compound of formula VI is then purified and reacted with diacetylguanine of formula VII, under conditions similar to those used to react the compound of formula V with diacetylguanine, to form 2-acetamido-9-(1,3-diacetoxy-2-propoxymethyl)hypoxanthine of formula IX as a viscous oil which is
10 crystallized by a procedure similar to that employed for the compound of formula VIII.



The compound of formula IX is then converted to the crystalline product of formula II by treatment similar to that employed to convert the compound of formula VIII to formula I.

25 It is also possible if desired, to separate glycerol formal into its constituent compounds of formulas III and IV wherein R in each case is H and then to treat each separated compound as described above.

30 It is equally possible to form a mixture of compounds of formulas V and VI from glycerol formal

by treating the latter directly with acetic anhydride in the presence of a catalyst, e.g., ZnCl_2 . The resulting mixture may be chromatographed by HPLC.

5 Fractions showing only the compound of formula V by analytical HPLC are concentrated under high vacuum and then reacted with diacetylguanine of formula VII as described above to give the compound of formula VIII which in turn is converted to the compound of formula I as described above.

10 Alternatively, the acetyl intermediates of formulas V and VI, each separately or as a mixture, can be converted to the more reactive halogen derivatives by treatment with hydrogen halide in a nonpolar solvent (hydrogen chloride in
15 dichloromethane is preferred) wherein the terminal $\text{AcOCH}_2\text{O-}$ functionality is transformed to $\text{XCH}_2\text{O-}$ where X is a halogen (chlorine, bromine, or iodine). These halogen compounds can be used in alkylation reactions with protected guanines [per(trimethyl-
20 silyl)guanine or diacetylguanine are two preferred derivatives] in nonpolar or dipolar solvents such as benzene, toluene, acetonitrile or dimethylformamide with or without an acid-acceptor substance such as triethylamine or powdered calcium carbonate as has
25 been described in the literature, for example, in U.S. Patent 4,199,574.

Chromatographic fractions containing primarily the compound of formula VI are rechromatographed by HPLC and those fractions of satisfactory
30 purity are combined, concentrated under high vacuum and then reacted with diacetylguanine of formula VII

as described above to give the compound of formula IX which in turn is converted to the compound of formula II as described above.

5 While the foregoing process description has referred specifically to compounds wherein the acyl group is acetyl, it is to be understood that the acyl group may equally be a straight or branched chain alkanoyl group of up to about 20 carbon atoms, which
10 may be saturated or mono- or polyunsaturated and optionally substituted by aryl, substituted aryl, heterocyclyl, aralkyl, alkoxyalkyl or aryloxyalkyl group.

The acyl derivatives are preferably prepared by reacting the compounds of formulas I or II with
15 the appropriate acyl halide, acid anhydride, or other activated acyl species in the presence of an appropriate cosolvent such as, for example, pyridine-dimethylformamide. 4-Dimethylaminopyridine is an effective catalyst. Other activated acyl species may
20 be prepared by reaction of the acid with a suitable activating agent such as, for example, 1,1'-carbonyl-diimidazole, N,N'-dicyclohexylcarbodiimide or by acylation of N-hydroxysuccinimide or 1-hydroxy-benzotriazole by known methods.

25 Compared to acycloguanosine, 9-(2-hydroxy-ethoxymethyl)guanine, the compounds of the present invention are more soluble and are more readily phosphorylated by viral enzymes, and have substantially greater activity in vivo than acycloquano-
30 sine. The compounds of the present invention may be employed as anti-viral compounds in mammalian or avian species either individually or in combination in dosage levels effective to impart an anti-herpes virus activity. Typically such levels are from about

0.01 to about 200 mg/kg/day. The compounds of the present invention may be formulated according to accepted pharmaceutical practice for administration orally, topically or by injection. Suitable oral
5 dosage forms are tablets, capsules, elixirs or powders, while solutions or suspensions in, for example, phosphate buffered saline or water are suitable for injection. Examples of suitable topical formulations are gels, ointments, solutions or suspensions.

10 The acyl derivatives (C_{1-20}) of the compounds of the present invention have antimycoplasmal activity and are useful in treating or preventing this disease in swine and poultry.

The following Examples illustrate the
15 present invention without, however, limiting the same thereto. All temperatures are expressed in degrees Celsius.

EXAMPLE 1

20 9-(2,3-Dihydroxy-1-propoxymethyl)guanine

A. Acetoxymethyl 2,3-Diacetoxy-1-propyl Ether

To a stirred mixture of 17.1 ml (20.8 g, 200 mmole) of glycerol formal containing a mixture of the compounds of formulas III and IV, there was added 60
25 ml of acetic anhydride, 6.7 ml of glacial acetic acid, and 2.0 g of anhydrous $ZnCl_2$. The mixture was stirred at ambient temperature under an N_2 atmosphere. The $ZnCl_2$ soon dissolved, and within a few minutes there was a strong exothermic reaction
30 with the color of the solution turning light amber. After one hour, by which time the exothermic reaction had subsided, thin layer chromatography (TLC) (1:1 and 2:1 hexane-ethyl acetate) showed an apparently complete and clean reaction. After 4.5 hours, the

solution was concentrated under high vacuum. The residual oil was taken up in 700 ml of diethyl ether and washed with 2 X 100 ml of a saturated NaHCO_3 solution, and then with 100 ml of H_2O . The ether solution was dried over MgSO_4 , decolorized with charcoal, and filtered. The filtrate was concentrated under high vacuum to give 45.8 g (92%) of colorless residual oil. Analytical HPLC (7:3 hexane-ethyl acetate) showed only the two product isomers of formula V and VI. The bulk of the two product isomers (44.5 g) was subjected to HPLC in four batches of from 11 to 11.5 g each. All runs were performed under identical conditions using silica gel (two Waters Prep-500 packs), 7:3 hexane-ethyl acetate (250 ml per minute flow rate) with recycling (three cycles) and refractive index detection. Fractions were cut in the same place for each run, and fractions from the various runs were combined as they were collected. No clear separation of peaks was observed on the refractive index trace.

Fractions identified by analytical HPLC as pure compound of formula V (shorter retention time) were combined and concentrated under high vacuum to give 17.0 g of a colorless residual oil whose NMR (CDCl_3) was consistent for acetoxymethyl 2,3-diacetoxy-1-propyl ether.

B. 2-Acetamido-9-(2,3-diacetoxy-1-propoxymethyl)-hypoxanthine

A mixture of 2.61 g (11.1 mmole) of diacetylguanine (VII), 5.50 g (22.2 mmole) of acetoxymethyl 2,3-diacetoxy-1-propyl ether from Step A above and 55 mg of ethanesulfonic acid was heated

in a flask fitted with a distillation adapter under low vacuum in an oil bath at 155-160°. The mixture gradually thinned enough to permit magnetic stirring, and some distillate was collected. The mixture
5 became homogenous after about 45 minutes and was cooled after 75 minutes. The viscous oil was taken up in about 100 ml of ethyl acetate and induced to crystallize with a yield of 1.23 g (29%) of nearly white crystals, mp 162.5-165°. Thin layer
10 chromatography (TLC) (9:1 CHCl₃-CH₃OH) showed a single spot.

C. 9-(2,3-Dihydroxy-1-propoxymethyl)guanine

A solution of 1.14 g (3.0 mmole) of 2-acetamido-9-(2,3-diacetoxy-1-propoxymethyl)hypoxanthine (VIII) from Step B above was heated at
15 reflux in 40% aqueous methylamine with stirring under N₂ for 1 hour and then cooled. TLC (80:20:2 CHCl₃-CH₃OH-H₂O) showed complete conversion to the title compound (I). The light orange solution
20 was treated with some charcoal and filtered through Super-Cel. Concentration of the filtrate gave a solid which was recrystallized from H₂O (adjusted to about pH 6 with a few drops of CH₃COOH) to yield 687 mg of cream-colored crystals, mp 246-247° dec.

25

EXAMPLE 2

9-(1,3-Dihydroxy-2-propoxymethyl)guanine

A. Acetoxymethyl 1,3-Diacetoxy-2-propyl Ether

After drying under high vacuum, fractions
30 from step A of Example 1 which were high in content of formula VI (longer retention time) were combined

to give 9.71 g of residual oil which was subjected to HPLC under the same conditions as described above. Fractions containing the compound of formula VI in satisfactory purity as determined by analytical HPLC
5 were combined and concentrated under high vacuum to give 5.01 g of an almost colorless residual oil. Analytical HPLC indicated a ratio of compound of formula VI to the compound of formula V of approximately 15:1 based on peak heights. The NMR (CDCl_3)
10 was consistent with this isomer ratio and was in accord with the identification of this compound as acetoxymethyl 1,3-diacetoxy-2-propyl ether.

15 B. 2-Acetamido-9-(1,3-diacetoxy-2-propoxymethyl) hypoxanthine

A mixture of 3.76 g (16 mmole) of diacetylguanine (VII), 4.96 g (20 mmole) of acetoxymethyl 1,3-diacetoxy-2-propyl ether (VI), 40 mg of ethanesulfonic acid, and 15 ml of triglyme in a flask
20 fitted with a distillation adapter was heated under low vacuum in an oil bath at 155-160°. The mixture gradually thinned enough to stir, and a clear distillate was slowly collected. The reaction mixture became a clear solution after about 75
25 minutes. After 3 hours the solution was cooled, and the product was induced to crystallize. After standing, the thick mixture was diluted with a small volume of 1,2-dimethoxyethane. The solid was collected on a filter and washed with small volumes
30 of 1,2-dimethoxyethane followed by ethyl acetate to give 3.27 g of cream-colored crystals consisting of a

mixture of 9- and 7-alkylated isomers as determined by TLC (9:1 CHCl_3 -MeOH). (The 9-isomer runs more slowly than the 7-isomer in this system.) The mother liquor provided an additional 0.65 g of material.

5 The combined crops (3.92 g) were chromatographed twice on a silica gel column (elution with 97:3 and then 96:4 CH_2Cl_2 -MeOH). Fractions containing nearly pure 9-alkylated isomer were combined and concentrated. Crystallization of the residues from a
10 minimum amount of 1,2-dimethoxyethane yielded a first crop of 665 mg (white crystals, mp 171.5-172.5°) and a second crop of 189 mg (mp 173-173.5°). Both crops consisted of the pure 9-alkylated product as determined by TLC in comparison with an earlier batch
15 fully characterized by NMR and elemental analysis.

C. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine

A solution of 838 mg (2.2 mmole) of 2-acetamido-9-(1,3-diacetoxy-2-propoxymethyl)-hypoxanthine in 8.5 ml of 40% methylamine (aqueous)
20 was stirred at gentle reflux under N_2 for 1 hour. The solution was then cooled and concentrated to dryness. The residual white solid was recrystallized from a minimum volume of H_2O containing 2 drops of acetic acid. After standing in the refrigerator, the
25 product was collected on a filter and washed with a small amount of H_2O , then acetone. The material was dried under high vacuum at 75° for 3 hours to give 529 mg (90% based on hydration with 0.75 H_2O) of white crystals, mp 249-250° dec. The material was
30 homogeneous by TLC (80:20:2 CHCl_3 -MeOH- H_2O), and the structure was confirmed by NMR.

EXAMPLE 3Acetoxymethyl 1,3-Diacetoxy-2-propyl EtherA. 1,3-Dioxan-5-yl Acetate and 1,3-Dioxolane-4-
5 methyl Acetate

10 A mixture of 10.0 g (96 mmole) of glycerol
formal, 8.35 g (105 mmole) of pyridine, and 20 ml of
acetic anhydride was stirred at ambient temperature
under protection from moisture. After a period
15 ranging from a few hours to 5 days, the solution was
fractionally distilled under vacuum. The early
fractions consisted primarily of pyridine, acetic
acid, and acetic anhydride. The bulk of the product
distilled at 56-57° (1.1 mm). The product fractions
20 (10.8 g) were separated into the 5- and 6-membered
ring isomers by preparative HPLC on silica gel in 3:1
hexane-ethyl acetate with recycling. Fractions were
identified and checked for purity by analytical
HPLC. In total 3.19 g (23%) of 1,3-dioxolane-
4-methyl acetate (shorter retention time) and 5.23 g
(37%) of 1,3-dioxan-5-yl acetate (longer retention
time) were obtained. The structures were confirmed
by NMR.

25 B. Acetoxymethyl 1,3-Diacetoxy-2-propyl Ether

A solution of 6.0 g (41 mmole) of 1,
3-dioxolane-4-methyl acetate and 0.4 g of zinc
chloride in a mixture of 12 ml of acetic anhydride
and 1.4 ml of glacial acetic acid was stirred at
30 ambient temperature under N₂. An exotherm
occurred, and after 1 hour TLC (2:1 hexane-ethyl

acetate) indicated complete reaction. The solution was concentrated under high vacuum. The resulting liquid was dissolved in ether and washed thoroughly with saturated NaHCO_3 solution, then with H_2O .
5 The ether layer was dried over MgSO_4 , filtered, and concentrated to give 8.68 g of residual oil consisting of a mixture of the compound of formula VI (major) and the compound of formula V (minor). This material was combined with 3.50 g from a similar
10 batch. The total of 12.18 g of crude product was purified by preparative HPLC on silica gel in 7:3 hexane-ethyl acetate with recycling. The fractions were checked for purity by analytical HPLC. Fractions of satisfactory purity were combined and
15 concentrated to give 5.84 g of the compound of structure VI ($\geq 90\%$ pure). The structure and purity were confirmed by NMR.

EXAMPLE 4

20 Bromomethyl 1,3-Diacetoxy-2-propyl Ether
Acetoxymethyl 1,3-diacetoxy-2-propyl ether (250 mg, 1 mmole) was dissolved in dichloromethane presaturated with hydrogen bromide gas at 0° . The mixture was protected from moisture and stirred at 0°
25 for 2 hours, then allowed to warm to ambient temperature with loss of excess hydrogen bromide. After three hours the solvents were removed under aspirator vacuum. The evaporation residue was treated successively with two 10 ml aliquots of
30 dichloromethane, which were evaporated under aspirator vacuum. Finally the residual oil was dried

under high vacuum until the sharp odor of hydrogen bromide was no longer evident. The resulting material may be used immediately in alkylation reactions. Proton magnetic resonance spectra of CDCl_3 solutions showed an appropriate downfield shift reflecting the change from AcOCH_2O to BrCH_2O .

EXAMPLE 5

Chloromethyl 1,3-Diacetoxy-2-propyl Ether

10 A solution of 4.34 g (17.5 mmole) of acetoxymethyl 1,3-diacetoxy-2-propyl ether in 45 ml of methylene chloride was stirred at room temperature as a gentle stream of HCl was passed through it. After 2 hours the HCl stream was removed. The flask
15 was stoppered and allowed to stir overnight at room temperature. Then the flask was placed in a water bath at 25-30°, and the solution was purged with a stream of N_2 to remove most of the excess HCl. The remaining solution was concentrated by rotary
20 evaporation. In order to remove traces of HCl, the residual oil was taken up in toluene and concentrated under high vacuum at room temperature. This process was repeated three more times. After vacuum drying at room temperature, the yield of colorless residual
25 oil was 3.83 g (97%). The NMR spectrum indicated complete conversion to product.

EXAMPLE 62-Acetamido-9-(1,3-diacetoxy-2-propoxymethyl) hypoxanthine

A mixture of 2.57 g (18 mmole) of guanine,
5 1.8 g of ammonium sulfate, and 126 ml of
hexamethyldisilazane was stirred at reflux under
 N_2 . The solid gradually dissolved. After 2 days
the solution was cooled and concentrated under high
vacuum. The viscous, residual oil was dissolved in
10 about 28 ml of dry toluene and maintained under N_2
as a solution of 5 g (22.3 mmole) of chloromethyl
1,3-diacetoxy-2-propyl ether in 12 ml of dry toluene
was added. The resulting solution was heated at
reflux under N_2 for 1.5 hours. It was then cooled,
15 concentrated, and dried under high vacuum. The
viscous, orange residual oil was treated with 30 ml
of water and 30 ml of saturated sodium bicarbonate
solution. The mixture was swirled with warming on a
steam bath for 5 minutes, during which time the
20 residue solidified. After cooling, the solid was
collected on a filter and washed with a small volume
of water. Although this cream-colored solid (4.6 g)
gave a single spot on TLC (80:20:2 $CHCl_3$ -MeOH- H_2O),
NMR showed that it contained 10-15% of the 7-alkylated
25 isomer in addition to the desired 9-isomer. The
material was combined with 0.6 g of similar material
from other runs and was suspended in 184 ml of acetic
anhydride. The mixture was heated at 97° for 18 hours
by which time nearly all of the solid had dissolved,
30 and TLC showed complete acetylation. The reaction was
cooled and concentrated under vacuum. Treatment of the

residue with 200 ml of methylene chloride gave a solid, which was isolated by filtration and washed once with methylene chloride. Recrystallization from methylene chloride gave 0.55 g of pure 9-isomer. The filtrates
5 were passed through a column containing 40 g of silica gel. Elution with 97:3 CH_2Cl_2 -MeOH gave 4.5 g of partially purified product. Upon recrystallization from methylene chloride (about 45 ml), 3.0 g of pure 9-isomer was obtained.

10

EXAMPLE 7

9-(1,3-Diacetoxy-2-propoxymethyl)guanine

A mixture of 50.0 g (0.33 mole) of guanine, 33 g of ammonium sulfate, and 2.2 l of hexamethyl-
15 disilazane was stirred at reflux under N_2 for 3 days, during which time all of the solid dissolved. The solvent was then removed by distillation under reduced pressure. To the very viscous, orange residual oil was added under N_2 84 g (0.34 mole) of
20 acetoxymethyl 1,3-diacetoxy-2-propyl ether, which formed a second liquid phase at the bottom of the flask. The flask was fitted with a distillation adapter, and the mixture was heated under low vacuum in an oil bath at approximately 135°. After an
25 induction period lasting several minutes, boiling began and soon became quite vigorous. Distillation of trimethylsilyl acetate (along with any residual hexamethyldisilazane) proceeded rapidly at first but slowed after 30 minutes. After 2 hours the mixture
30 was added to 1.3 l of 90% EtOH. The mixture was heated to boiling and maintained there until the

separated gummy material was transformed to a tractable solid. The solid (8.2 g, consisting almost exclusively of guanine) was removed by filtration while hot. The filtrate was allowed to stand overnight, resulting in separation of an orange-brown gum. The supernatant was decanted away from the gum, filtered, and then concentrated to small volume. The solid which separated on concentration was collected on a filter and washed with H_2O , then with some EtOH, to give 15.4 g of cream-colored crystals. By NMR, this material was solely the 9-alkylated isomer, although TLC indicated partial side chain deacetylation. The material was suitable for deprotection without further purification.

Further processing of the mother liquor, and of the gum which had been removed by decantation, gave additional crops consisting of varying ratios of 9- and 7-alkylated isomers (partially deacetylated). These less pure crops were preferably converted to fully acetylated derivatives (0,0',N²-triacetyl) prior to chromatographic purification (silica gel, elution with CH_2Cl_2 -MeOH). Typical acetylation conditions consisted of stirring a mixture of 10 g of the crude guanine derivative and 400 ml of acetic anhydride at 95-100° overnight, followed by concentration and chromatography.

EXAMPLE 8

9-(1,3-Diacetoxy-2-propoxymethyl)guanine

A mixture of 205 mg (0.75 mmole) of 9-(1,3-dihydroxy-2-propoxymethyl)guanine monohydrate,

1.5 ml of acetic anhydride, 6 ml of dry dimethylformamide, and 1.5 ml of dry pyridine was stirred at room temperature under a drying tube for 4 days.

Then the mixture was diluted with 15 ml of Et₂O.

- 5 The solid was collected on a filter and washed with Et₂O. After recrystallization from 2-methoxyethanol, yield of colorless crystals = 149 mg (59%), m.p. 239-240°. The material was homogenous by TLC (9:1 CHCl₃-MeOH), and NMR confirmed the assigned
10 structure.

Anal. (C₁₃H₁₇N₅O₆). Calcd.: C, 46.01; H, 5.05; N, 20.64.

Found: C, 45.71; H, 5.04;

- 15 N, 20.36.

EXAMPLE 9

9-(1,3-Dipropionyloxy-2-propoxymethyl)guanine

A mixture of 205 mg (0.75 mmole) of

- 20 9-(1,3-dihydroxy-2-propoxymethyl)guanine monohydrate, 1.5 ml of propionic anhydride, 6 ml of dry dimethylformamide, and 1.5 ml of dry pyridine was stirred at room temperature under a drying tube. After 4 days the mixture was diluted with 25 ml of ether.
25 The solid was collected on a filter and washed with ether. Recrystallization from isopropanol gave 136 mg (50%) of white crystals, m.p. 196-197.5°. The material ran as a single spot on TLC (9:1 CHCl₃-MeOH), and the
30 structure was confirmed by NMR.

Anal. ($C_{15}H_{21}N_5O_6$). Calcd.: C, 49.04; H, 5.76;
N, 19.07

Found: C, 48.96; H, 5.83;
N, 19.26.

5

EXAMPLE 109-(1-Hydroxy-3-octanoyloxy-2-propoxymethyl)guanine

A suspension of 410 mg (1.5 mmole) of
9-(1,3-dihydroxy-2-propoxymethyl)guanine monohydrate
10 in 6 ml of dry dimethylformamide and 1.5 ml of dry
pyridine was stirred under a drying tube with cooling
in an ice bath as a solution of 489 mg (3.0 mmole) of
octanoyl chloride in 1.5 ml of dimethylformamide was
added dropwise by syringe over approximately 5
15 minutes. The mixture was allowed to warm gradually
to room temperature, and after 24 hours it was
concentrated under high vacuum. The residual oil was
purified by preparative TLC on nine 1000- μ silica gel
plates (developed in 5:1 $CHCl_3$ -MeOH). The product
20 bands were isolated, combined, and extracted with
dimethylformamide. Concentration of the extracts
under high vacuum gave a gummy residue.
Crystallization from isopropanol gave a material
which again turned gummy on the filter. However,
25 thorough trituration with ether yielded 105 mg (18%)
of very pale yellow crystals, m.p. 201.5-203.5°.

EXAMPLE 119-(1,3-Dioctanoyloxy-2-propoxymethyl)guanine

30 A suspension of 137 mg (0.5 mmole) of 9-(1,3-
dihydroxy-2-propoxymethyl)guanine monohydrate in 2.8 ml of

dry dimethylformamide and 0.7 ml of dry pyridine was stirred at room temperature as 244 mg (1.5 mmole) of octanoyl chloride was added. The addition was accompanied by a mild exotherm, and a clear solution was obtained. An additional 82 mg (0.5 mmole) of octanoyl chloride was added after 3.5 hours. Finally, after 21 hours, the solution was concentrated under high vacuum. The residue was partitioned between 5 ml of methylene chloride and 5 ml of water. The methylene chloride phase was dried over magnesium sulfate, filtered, and concentrated to give a pale yellow residual oil, which solidified on standing. This material was purified by preparative TLC on five 2000- μ silica gel plates (developed in 12:1 CHCl_3 -MeOH). The product bands were isolated and extracted with methanol. The residue obtained on concentration of the extracts was taken up in ether and filtered. Evaporation of the filtrate followed by drying under high vacuum yielded 162 mg (64%) of pale yellow-orange, glossy residue. Purity and structure were confirmed by TLC (12:1 CHCl_3 -MeOH), NMR, and mass spectrum.

This compound gave a 75% inhibition of mycoplasmal growth in chickens when administered systemically at a dosage level of 875 $\mu\text{g}/\text{bird}$.

EXAMPLE 12

Sodium 9-(1,3-Dihydroxy-2-propoxymethyl)guanine cyclic monophosphate

A suspension of 5.91 g (23.2 mmoles) of anhydrous 9-(1,3-dihydroxy-2-propoxymethyl)-

guanine in a solution of 3.6 g (2.2 ml; 23.6 mmoles) of phosphorous oxychloride in 60 ml of anhydrous triethyl phosphate was stirred at room temperature for five hours. The largely clarified mixture was filtered, and the filtrate was poured into 600 ml of stirred hexane. After about five minutes the supernatant hexane was decanted from the precipitated product, and the residue was heated with a second 600 ml portion of hexane. After the supernatant hexane was decanted and the residue was dried in vacuo, 15.9 g of a solid product was obtained. The solid was largely dissolved in 800 ml of deionized water and the cloudy mixture was titrated to pH 7 with 5N potassium hydroxide and then 1N potassium hydroxide. The neutralized mixture was filtered and the filtrate was lyophilized yielding 9.25 g of product.

A specimen of the lyophilization residue was analyzed by high performance liquid chromatography using a Whatman PartisilTM PXS 10/25 SAX ion exchange column with 0.05M pH 6.6 phosphate buffer elution and ultraviolet absorption detection at 252 nm. The product exhibited three peaks with retention times of about 4 minutes, 7 minutes and 9 minutes. After authentic specimens of sodium and potassium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic and acyclic monophosphate were isolated as disclosed in this and other examples in this patent application and subjected to high performance liquid chromatography in the above system, the cyclic monophosphate was associated with a retention time of

about 4 minutes and the acyclic phosphate with a retention time of about 7 minutes.

The lyophilized mixture of potassium salts was dissolved in 1 liter of deionized water and filtered through a fluted filter paper. The filtrate was slowly passed through a 4-5 cm diameter column of 460 ml (644 milliequivalents) of 200-400 mesh Bio Rad AG1-X8 anion exchange resin on the bicarbonate cycle. Next, a gradient of 0.05M-0.5M potassium bicarbonate from a gradient elution chamber containing 2 liters of 0.05M and 0.5M potassium bicarbonate was pumped through the column and fractions of about 20 ml were collected at 8-minute intervals. At fraction 191, the eluent was changed to 0.5M potassium bicarbonate and samples of 20-25 ml were collected at 6.8-minute intervals. The elution pattern was monitored by ultraviolet absorption at 252 nm and certain component fractions of the various elution peaks were further characterized by high performance liquid chromatography in the Whatman PartisilTM PXS 10/25 SAX ion exchange column using 0.05M pH 6.6 phosphate elution. On the basis of these data certain fractions were combined and worked up as follows:

Fractions 450-540 (1680 ml) characterized by a single peak with a retention time of about 5 minutes in the above high performance liquid chromatography system, were combined and treated with 600 ml (1020 milliequivalents) of 200-400 mesh Bio Rad AG50W-X8 cation exchange resin on the acid cycle. The stirred mixture was kept under a modest


vacuum to remove carbon dioxide before it was filtered. The mixture was filtered and the resin was washed with small portions of deionized water. The combined filtrates were concentrated to a 150 ml
5 volume in vacuo at about 35° and the precipitated product, in the form of the free acid, was isolated by filtration and dried in vacuo to yield 445 mg of 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate. The product was crystalline according
10 to microscopy in polarized light, showed an ultraviolet absorption maximum at 252 nm (ϵ 10600, in 0.1M pH 7 phosphate), and gave a nuclear magnetic resonance spectrum fully in accord with the projected structure. Concentration of the mother liquors
15 yielded an additional 46 mg of the free acid form of the product. Titration of the mother liquors to pH 7 followed by lyophilization yielded 196 mg of sodium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate. The latter compound, may at times be
20 contaminated with small amounts of water soluble inorganic salts and may be purified by exclusion chromatography or by ion exchange chromatography on Bio Rad AG1-X8 anion exchange resin on the formate cycle.

25 The pure sodium salt was also obtained by titration of the crystalline free acid as follows:


A suspension of 213 mg of crystalline 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate was titrated to pH 7 with 1N sodium
30 hydroxide and the solution was lyophilized yielding 227 mg of sodium 9-(1,3-dihydroxy-2-propoxy-

methyl)guanine cyclic monophosphate. A dried sample of this product had an ultraviolet absorption maximum at 252 nm (11800 in 0.1M pH 7 phosphate).

- 5 The 200 MHz NMR spectrum of the cyclic product in D₂O is characterized by signals from two equivalent methylenes that have shifted downfield on monophosphorylation. The spectrum is characterized by the following chemical shifts.

10	δ3.94		m	1H	
15	δ4.25	P-O-CH eq	d,d,d	2H	(JH,H gem 12.5 Hz) (JP-OCH eq 19.5 Hz) (JH,H vic eq 2.2 Hz)
20	δ4.39	P-O-CH _{ax}	d,d,d	2H	(JH,H gem 12.5 Hz) (JP-OCH ax 5.0 Hz) (JH,H vic ax 1.8 Hz)
	δ5.64	N-CH ₂ O	s	2H	
	δ7.99	C ₈ -H	s	1H	

- 25 Additional confirmation of structure is obtained when the predicted pattern of shifts is realized for the P-O-CH₂ groups on irradiation of the



In a Varian AX-10 high performance liquid chromatography anion exchange column using a gradient of 10-1000 mM unbuffered KH_2PO_4 , the cyclic product has a retention time of 4.3 minutes whereas the enzymically derived acyclic monophosphate has a retention time of 4.8 minutes. The synthetic cyclic monophosphate is clearly separated from the acyclic enzymically-derived monophosphate when a mixture of the two is subjected to HPLC in the above system.

As an alternative, the sodium or potassium salt of the cyclic monophosphate may be isolated from the Bio Rad AG1-X8 bicarbonate eluate fractions without isolation of the crystalline free acid. A combination of fractions amounting to about 800 ml of 0.5M KHCO_3 was treated with 325 ml (552 mmoles) of 200-400 mesh AG50W-X8 cation exchange resin on the acid cycle. The stirred mixture was kept under modest vacuum for fifteen minutes to remove carbon dioxide and was filtered. The filtrate was concentrated to about a 100 ml volume which was then titrated to pH 7 with 1N sodium hydroxide. Lyophilization of the resulting solution yielded 529 mg of the sodium salt of the cyclic phosphate that was contaminated with a small amount of water soluble inorganic salts.

To desalt the product, 200 mg of the sodium salt was dissolved in 1.5 ml of deionized water and put on a 1.5 cm diameter column of 6 ml of Bio Rad 200-400 mesh AG1-X8 anion exchange resin on the formate cycle. After about 35 ml of deionized water was passed through the column, elution was begun with

2N ammonium formate solution. Fractions of 3.5 ml volume were collected at 3 minute intervals and the ultraviolet absorption at 250 nm of each fraction was measured and plotted versus tube number. On the basis of the shape of the curve obtained in the above plot, fractions 13-28 were combined and put on a 2-3 cm diameter column of 120 ml (204 milliequivalents) of 200-400 mesh Bio Rad AG50W-X8 cation exchange resin. The column was eluted with water and 13.5 ml fractions were collected at 4.5-minute intervals. The elution pattern was monitored by ultraviolet absorption at 252 nm and on the basis of the plot, fractions 22-40 were combined and concentrated to dryness. The residue was taken up in 10 ml of deionized water and titrated to pH 7 with 0.1N NaOH. Lyophilization of the neutralized solution yielded 106 mg of sodium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate.

20

EXAMPLE 13

Disodium 9-(1,3-dihydroxy-2-propoxymethyl)-
guanine acyclic monophosphate

Preparation 1

In the phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine with phosphorus oxychloride to yield the corresponding cyclic monophosphate, the crude condensation product was purified by ion exchange chromatography on Bio Rad AG1-X8 (CO_3^-). In the course of elution with 0.5 M potassium bicarbonate as described in the example for preparation of the cyclic monophosphate, a discrete

peak consisting of fractions 245-248 was separated and found to contain the corresponding acyclic compound dipotassium 9-(1,3-dihydroxy-2-propoxymethyl)guanine acyclic monophosphate. Using a
5 PartisilTM PXS 10/25 SAX high performance liquid chromatography column and elution with 0.05M pH 6.6 phosphate buffer, this peak contained material with retention times of about 5 and 8 minutes. The authentic acyclic monophosphate is associated with a
10 retention time of 7-8 minutes in the same system. Analysis of this combination of fractions on a Varian AX-10 high performance liquid chromatography anion exchange column using gradient elution with 10-400 mM unbuffered KH_2PO_4 showed that about 40% of the
15 material was dipotassium 9-(1,3-dihydroxy-2-propoxymethyl)guanine acyclic monophosphate.

Preparation 2

A solution of 44.5 mg of sodium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic mono-
20 phosphate in 4 ml of 5N sodium hydroxide was heated at 55-60°C under a nitrogen blanket for eight hours. The reaction mixture was diluted to a 12 ml volume with deionized water and passed slowly through a 30 ml (2 cm diameter X 12 cm length) column of Bio Rad
25 AG50W-X8 cation exchange resin on the sulfonic acid cycle. The column was eluted with deionized water and 5 ml fractions were collected at 4-minute intervals. After fraction 60 was collected, 12 ml fractions were collected every 4 minutes. The
30 various fractions were evaluated by ultraviolet absorption at 252 nm and also by high performance

liquid chromatography on a PartisilTM PXS 10/25 SAX anion exchange column using 0.05M pH 6.6 phosphate buffer elution. Fractions 45-64, which consisted exclusively of material with a retention time of about 7.5 minutes were combined, titrated to pH 7 with 0.1N sodium hydroxide and then lyophilized to yield 30 mg of disodium 9-(1,3-dihydroxy-2-propoxymethyl)guanine acyclic monophosphate. A 200 MHz nuclear magnetic spectrum of the product in deuterium oxide is fully in accord with the acyclic monophosphate structure. Anal. Calcd. for $C_9H_{12}N_5O_7PNa_2$ (379.19) N, 18.47; C, 28.51; H, 3.19; P, 8.17; Na, 12.13. Found: N, 18.07; C, 28.67; H, 3.36; P, 8.51, Na 11.90 (by atomic absorption). λ_{max} 252 nm, ϵ , 9600 (0.1M pH 7 phosphate).

EXAMPLE 14

9-[1,3-Bis(phenoxycetoxy)-2-propoxymethyl]guanine

A suspension of 273 mg (1.0 mmole) of 9-(1,3-dihydroxy-2-propoxymethyl)guanine monohydrate in 4 ml of dry dimethylformamide and 1.4 ml of dry pyridine was stirred under nitrogen with cooling in an ice bath as a solution of 552 μ l (682 mg, 4 mmole) of phenoxycetyl chloride in 1.6 ml of dimethylformamide was added dropwise by syringe through a septum over a period of 10 minutes. After the ice had melted, the mixture was allowed to warm gradually to room temperature. A pale yellow solution was obtained. After 15 hours the solution was concentrated under high vacuum with mild

warming. The golden residual oil was chromatographed on a silica gel column (gradient elution from 98:2 CH_2Cl_2 -MeOH to 92:8 CH_2Cl_2 -MeOH). Fractions containing nearly pure product were combined and concentrated to give an oil which solidified on trituration with ether-acetone. Recrystallization from a small volume of acetonitrile gave 114 mg of white crystals, m.p. 114-116°. Structure and purity were confirmed by NMR and TLC (9:1 CHCl_3 -MeOH). A second crop of 66 mg was obtained from the mother liquor.

Anal. ($\text{C}_{25}\text{H}_{25}\text{N}_5\text{O}_8$). Calcd.: for 93.5% $\text{C}_{25}\text{H}_{25}\text{N}_5\text{O}_8 \cdot \text{H}_2\text{O}$ + 6.5% inorganic, C, 51.84; H, 4.70, N, 12.09.

Found: C, 51.94; H, 4.74; N, 11.99.

EXAMPLE 15

9-(2,3-Dibenzoyloxy-1-propoxymethyl)guanine

A suspension of hydrated 9-(2,3-dihydroxy-1-propoxymethyl)guanine (1 mmole) in 4 ml of dry dimethylformamide and 1.4 ml of dry pyridine is stirred under nitrogen in an ice bath as a solution of benzoyl chloride (4 mmole) in 1.6 ml of dimethylformamide is added dropwise. The mixture is allowed to warm gradually to room temperature. After stirring overnight, the solution is concentrated under high vacuum. The residue is chromatographed on silica gel (elution with CH_2Cl_2 -MeOH) to give the product. Structure and purity are confirmed by NMR and TLC (9:1 CHCl_3 -MeOH).

EXAMPLE 169-(1,3-Diisovaleryloxy-2-propoxymethyl)guanine

A suspension of hydrated 9-(1,3-dihydroxy-2-propoxymethyl)guanine (1 mmole) in 4 ml of dry dimethylformamide and 1.4 ml of dry pyridine is stirred under nitrogen in an ice bath as a solution of isovaleryl chloride (4 mmole) in 1.6 ml of dimethylformamide is added dropwise. After warming gradually to room temperature, the mixture is stirred overnight. The resulting solution is evaporated under high vacuum with mild warming. Chromatography of the residue on silica gel (elution with CH_2Cl_2 -MeOH) gives the product. Structure and purity are confirmed by NMR and TLC (9:1 CHCl_3 -MeOH).

EXAMPLE 179-[1,3-Bis(phenylacetoxyl)-2-propoxymethyl]guanine

The compound is prepared by reaction of hydrated 9-(1,3-dihydroxy-2-propoxymethyl)guanine (1 mmole) with phenylacetyl chloride (4 mmole) according to the procedure used for 9-[1,3-bis(phenoxyacetoxyl)-2-propoxymethyl]guanine (Example 14). After chromatography the product is characterized by NMR and TLC (9:1 CHCl_3 -MeOH).

EXAMPLE 189-[1,3-Bis(10-undecenoyloxy)-2-propoxymethyl]guanine

The compound is prepared by reaction of hydrated 9-(1,3-dihydroxy-2-propoxymethyl)guanine (1 mmole) with 10-undecenoyl chloride (4 mmole)

according to the method used for 9-[1,3-bis(phenoxy-
acetoxymethyl)guanine (Example 14). The
product is obtained after chromatography. Structure
and purity are confirmed by NMR and TLC (9:1
5 CHCl_3 -MeOH).

EXAMPLE 19

9-[1,3-Bis(methoxyacetoxymethyl)guanine

Reaction of hydrated 9-(1,3-dihydroxy-
10 2-propoxymethyl)guanine (1 mmole) with methoxyacetyl
chloride (4 mmole) according to the method used for
9-[1,3-bis(phenoxyacetoxymethyl)guanine
(Example 14) gives, after chromatography, the desired
product. Confirmation of structure and purity are
15 obtained by NMR and TLC (9:1 CHCl_3 -MeOH).

EXAMPLE 20

9-[1,3-Bis(imidazol-1-ylcarbonyloxy)-2-propoxymethyl]- guanine

A mixture of 55 mg (0.2 mmole) of
20 9-(1,3-dihydroxy-2-propoxymethyl)guanine monohydrate,
130 mg (0.8 mmole) of 1,1'-carbonyldiimidazole, and 2
ml of dry dimethylformamide was stirred under
nitrogen at 95-100° for 1.5 hours, during which time
25 a clear solution was obtained followed by
precipitation of product. After cooling, the
precipitate was collected on a filter and washed with
some dimethylformamide and then with acetone to give
37 mg of white crystals, m.p. 252-253° dec. The NMR
30 spectrum was in accord with the assigned structure.
Anal. ($\text{C}_{17}\text{H}_{17}\text{N}_9\text{O}_6$). Calcd.: C, 46.05; H,
3.87; N, 28.43;
Found: C, 45.68; H, 3.90; N, 28.18.

EXAMPLE 21Comparative Solubilities in pH 7.2 Buffer at 25°

Solubilities were determined by suspending
5 an excess amount of the compound in approximately
0.15 molar phosphate buffer (pH 7.2) and shaking
overnight in a water bath at 25° to give a saturated
solution. The concentration of the compound in the
10 filtered solution was calculated on the basis of
spectrophotometric measurements, i.e. comparison of
the ultraviolet absorbance at the λ_{max} for the
saturated solution with the absorbance value observed
for a known concentration of the compound. The
results were summarized as follows:

15

<u>Compound</u>	<u>Solubility (mg/ml)</u>
Acycloguanosine	1.3-1.5
Compound of Formula I	3.6
Compound of Formula II	2.8

20

EXAMPLE 22

Phosphorylation of Compounds of Formula I and II and
of Acycloguanosine by Herpes virus-induced Thymidine
25 Kinase

30 μg of compound of formula I dissolved in
30 μl of 50% dimethylsulfoxide (DMSO) were incubated
in a final volume of 150 μl for 3 hours at 37° with
50 mM Tris-HCl buffer, pH 7.5, 2.5 mM adenosine
30 triphosphate, 2.5 mM magnesium chloride, 7.5 mM
phosphocreatine, 2 units of creatine kinase, 2 mM

dithiothreitol, 2.5 mM sodium fluoride, 50 μ g of bovine serum albumin and 0.0014 units of thymidine kinase, isolated from virus-infected HeLa cells (HSV1 virus), at a multiplicity of 10, (10 virus particles per cell), harvested 8 hours post infection) by the method of CHENG & OSTRANDER (Journal of Biological Chemistry, 1976, vol. 251, p 2605).

Two similar mixtures, one containing 30 μ g of compound of Formula II and the other 30 μ g of acycloguanosine, both in 50% DMSO were similarly treated.

A fourth mixture, similar to the above but containing only 30 μ l of 50% DMSO and no anti-viral compound was also treated similarly as a control.

At the end of the 3 hour incubation period, 10 μ l samples of each of the mixtures were analyzed by HPLC using an AX-10 column and a potassium phosphate (KH_2PO_4) gradient elution (0.01 to 1.0 M). The amount of the monophosphate derivative of each anti-viral compound was estimated by integration of the area under the respective chromatographic peaks. The results indicated that 16% of acycloguanosine was converted to the monophosphate derivative while 90% of compound of formula I and 95% of compound of formula II were converted to the respective monophosphates under the same conditions.

To the rest of the incubation mixtures were now added 0.04 units of guanosine monophosphate kinase and 20 μ l of an extract of HSV1-infected HeLa cells [The cells were infected with the virus at a multiplicity of 10 and harvested 8 hours later; they

were suspended in a solution containing 0.35 M KH_2PO_4 , pH 7.5, 0.5 mM dithiothreitol, 0.2% polyoxyethylene(9)octylphenol (Nonidet P-40), 14% glycerol at 50 mg/ml and after 30 minutes at 4° were centrifuged at 100,000 g; the supernatant liquid was the crude extract.] Incubation was continued at 30° for 4 more hours, after which samples were analyzed by HPLC and the amount of the triphosphate derivatives of each compound determined by integration of the area under the respective chromatographic peak. The results indicated that 31% of acycloguanosine was converted to the triphosphate under these conditions as compared to a conversion of 55% of compound of formula I and 93% of compound of formula II to the respective triphosphate derivatives.

Since phosphorylation is presumed to be a prerequisite for the anti-viral activity of these compounds, the higher rate of phosphorylation of compounds of formula I and II to the monophosphate and triphosphate derivatives represents a considerable improvement over acycloguanosine.

EXAMPLE 23

Enzymatic Preparation of the Acyclic Monophosphate of Compound of Formula II

The compound of formula II (25 mg) was incubated at 37° in a mixture containing: 50 mM potassium phosphate buffer at pH 6.5; bovine serum albumin, 1 mg/ml; adenosine triphosphate, 5 mM; magnesium chloride,, 5 mM; dithiothreitol, 1 mM; phosphocreatine, 1 mM; creatine kinase, 12.5

units/ml; sodium fluoride, 2.5 mM; and 500 units of purified HSV1-induced thymidine kinase, in a total volume of 10 ml. The progress of the reaction was monitored by high performance liquid chromatography (HPLC). When 35% of compound II had been converted to the monophosphate, the reaction was terminated. The product was purified by HPLC chromatography on a preparative anion exchange column (AX-10, Varian) and desalted by chromatography on diethylaminoethyl cellulose (DEAE) with triethylammonium carbonate pH 7.6 as the eluting solvent. Freeze-drying of the solvent from the pooled fractions containing the product yielded 8 mg of compound of formula II monophosphate, the purity of which was confirmed by analytical HPLC.

EXAMPLE 24

Enzymatic Preparation of the Diphosphate of Compound of Formula II

The compound of formula II (20 mg) was incubated at 37° in a 10 ml mixture containing: 50 mM potassium phosphate buffer at pH 6.5; bovine serum albumin, 1 mg/ml; adenosine triphosphate, 5 mM; magnesium chloride, 5 mM; dithiothreitol, 1 mM; phosphocreatine 1 mM; creatine kinase, 12.5 units/ml; sodium fluoride, 2.5 mM; 500 units of purified HSV1-induced thymidine kinase and 100 µg of guanosine monophosphate kinase from hog brain. The progress of the reaction was monitored by high performance liquid chromatography (HPLC). The incubation was continued for 4 hours at 37° and 20 hours at 30°. The pyrophosphate product was purified by HPLC chromatography on

a preparative anion exchange column (AX-10, Varian) and desalted by chromatography on diethylaminoethyl cellulose (DEAE) with triethylammonium carbonate, pH 7.6 as the eluting solvent. Freeze-drying of the solvent from the pooled fractions containing the product yielded 10 mg of compound of formula II diphosphate, the purity of which was confirmed by analytical HPLC.

10

EXAMPLE 25Enzymatic Conversion of the Diphosphate of Compound of Formula II to the Linear Triphosphate

The diphosphate of compound of formula II (5 mg), prepared as in Example 23, was incubated at 37° in a 5 ml mixture containing: Tris-acetate buffer, pH 7.6, 50 mM; magnesium chloride, 3 mM; ethylenediamine tetraacetic acid (EDTA) 1 mM; potassium phosphate, pH 7.5, 30 mM; pyruvate, 5 mM; glyceraldehyde phosphate, 30 mM; lactic dehydrogenase, 150 µg; glyceraldehyde phosphate dehydrogenase, 150 µg; 3-phosphoglycerate kinase, 150 µg; and nicotinamide adenine dinucleotide (NAD⁺), 15 mM. The progress of the reaction was monitored by high performance liquid chromatography (HPLC). Incubation was continued for 4 hours at 37° and 20 hours at 30°. The product was isolated by HPLC chromatography on an anion exchange column (AX-10, Varian) and desalted by chromatography on diethylaminoethyl cellulose (DEAE), with triethylammonium carbonate, pH 7.6 as the eluting solvent. Freeze-drying of the pooled fractions

containing the product yielded 4 mg of the triphosphate of compound of formula II, the purity of which was confirmed by analytical HPLC.

5

EXAMPLE 26Enzymatic Preparation of the Triphosphate of Compound of Formula II

The compound of formula II (20 mg) was incubated at 37° in a 10 ml mixture containing:

10 Tris-HCl, pH 7.5, 50 mM; magnesium chloride, 2.5 mM; adenosine-5'-triphosphate, 2.5 mM; bovine serum albumin, 500 mg/ml; dithiothreitol, 2 mM; phosphocreatine, 7 mM; creatine kinase, 12.5 units/ml; sodium fluoride, 2.5 mM; HSV1-induced

15 thymidine kinase, 400 units; and guanosine monophosphate kinase, 80 µg. Incubation was continued for 4 hours at 37° and for 20 hours at 30°. The progress of the reaction was monitored by analytical high performance liquid chromatography.

20 The product was isolated by HPLC chromatography on a preparative anion-exchange column (AX-10, Varian) and then rechromatographed on an analytical column, (Zorbax-NR₂) to remove contaminating ATP. The product was desalted by chromatography on

25 diethylaminoethyl cellulose (DEAE) with triethylammonium carbonate pH 7.6 as the eluting solvent. Freeze-drying of the pooled fractions containing the product yielded 15 mg of the triphosphate derivative of compound of formula II,

30 the purity of which was confirmed by analytical HPLC.

EXAMPLE 27Competition Between Thymidine and Acycloguanosine or
Compound of Formula II for Phosphorylation by the
Virus-Induced Thymidine Kinase

5 (1) 20 µg of acycloguanosine dissolved in
20 µl of 50% DMSO was incubated in a total volume of
120 µl (0.75 mM) with 80 mM Tris-HCl, pH 7.5, 4 mM
adenosine triphosphate, 4 mM magnesium chloride, 1.7
10 mM dithiothreitol, 12.5 mM phosphocreatine, 5.0 mM
sodium fluoride, 100 µg bovine serum albumin, 2.5
units of creatine kinase and 0.006 units of thymidine
kinase, isolated from HSV1-infected HeLa cells (as
per Example 22). Incubation was carried out at 37°
for 2 hours and then continued at 30° for 18 hours.

15 (2) A second mixture containing the same
ingredients as mixture No. 1 plus 2.5 mM thymidine
was incubated in the same manner.

20 (3) A third mixture containing the same
ingredients as mixture No. 1 but with 20 µg of
compound of formula II replacing the acycloguanosine
was incubated in the same manner.

 (4) A fourth mixture containing the same
ingredients as mixture No. 3 plus 2.5 mM thymidine
was incubated in the same manner.

25 At the end of the incubation the amount of
each anti-viral compound converted to the correspond-
ing monophosphate derivative was determined after
HPLC analysis by integration of the areas under the
chromatographic peaks (column and elution conditions
30 as in Example 22).

 The percent of monophosphate present at the
end of incubation in the four mixtures was as follows:

	<u>Mixture No.</u>	<u>Compounds</u> <u>present</u>	<u>Percent</u> <u>monophosphate</u>
5	1	Acycloguanosine	27
	2	Acycloguanosine & Thymidine	0
	3	Compound of Formula II	93
	4	Compound of Formula II & Thymidine	23

10

The results indicated that compound of formula II is phosphorylated by the viral thymidine kinase even in the presence of a large excess of thymidine whereas acycloguanosine was not phosphorylated at all under the same conditions. Since phosphorylation is a prerequisite for the anti-viral activity of these compounds and since thymidine is a normal constituent of the cells, the compound of formula II represents a significant improvement over acycloguanosine.

20

EXAMPLE 28

Comparison of the Kinetic Parameters of Acycloguanosine and Compound of Formula II with Purified Viral Thymidine Kinase

25

A series of mixtures containing in a total volume of 100 μ L: 22 μ moles KPO_4 buffer at pH 6.5; 0.3 μ moles $MgCl_2$; 0.5 μ moles of adenosine triphosphate; 100 μ g of bovine serum albumin; 20 units of HSV1-induced thymidine kinase and varying amounts of either compound of formula II or acycloguanosine, labeled with radioactive carbon

30

(^{14}C) at position 8 of the guanine ring were incubated for 15 minutes at 37° . At the end of this period, 80 μL aliquots from each tube were applied to circular filter papers (2.5 cm diameter) of diethylaminoethyl cellulose (Whatman DE81). Five minutes later, the filters were placed into a beaker with water and washed successively once with water, twice with 50% ethanol containing 0.5 mM quanosine, and once with absolute ethanol. They were then placed in scintillation vials, dried in a stream of air, and counted in a scintillation counter after addition of scintillation mixture (Aquasol 2, New England Nuclear). By this procedure, unphosphorylated compounds were washed away and only phosphorylated derivatives adhered to the DE81 filters; thus the radioactivity counted was a measure of the conversion of the substrates, compound of formula II or acycloquanosine, to their phosphorylated derivatives by the action of the viral thymidine kinase. Proper controls for background radioactivity were included in the assays and used to correct the results.

The number of moles of phosphorylated derivatives present in each assay tube at the end of the incubation period was calculated from the number of counts of radioactivity measured for each filter and the specific activity (counts per minute per mole) of each substrate in the assay mixtures. The data were plotted in a graph of reaction velocity versus substrate concentration. Figure 1 is a graph of the computer-generated theoretical curves best

fitting the actual experimental data. The curve obtained in a similar experiment with thymidine as the substrate is included in Figure 1 for comparison.

The kinetic parameters K_m , V_{max} and V_{max}/K_m for the two substrates were computed from the same data. The values obtained by averaging three separate experiments like the one described above were as follows:

	<u>Compound of formula II</u>	<u>Acycloguanosine</u>
K_m (μM)	66	426
V_{max} (pmoles/min)	280	61
V_{max}/K_m	4.25	0.14

Inasmuch as the ratio V_{max}/K_m is the most commonly used measure for comparing substrate efficiencies, the relative efficiencies of compound of formula II and acycloguanosine as substrates for the HSV1-induced thymidine kinase are 4.25 to 0.14 or 30 to 1.

EXAMPLE 29

Comparison of the Kinetic Parameters of Acycloguanosine and Compound of Formula II with Purified Guanosine Monophosphate Kinase

A series of mixtures containing in a total volume of 700 μl : 70 $\mu moles$ Tris-acetate buffer at pH 7.6; 70 $\mu moles$ KCl; 7 $\mu moles$ $MgCl_2$; 2.8 $\mu moles$ ATP; 1.05 $\mu moles$ phosphoenolpyruvate; 175 μg bovine serum albumin; 0.15 $\mu moles$ reduced nicotinamide-adenine dinucleotide (NADH); 3 units lactic dehydrogenase; 1.5

units pyruvate kinase; and varying amounts of either acycloguanosine monophosphate or the monophosphate of compound of Formula II are incubated at 25° with guanosine monophosphate kinase from hog brain (Boehringer-Mannheim) in the cuvette of a Cary spectrophotometer recording the absorbance at 340 nm. In this coupled spectrophotometric assay the rate of phosphorylation of the monophosphate substrates to the corresponding diphosphates is calculated from the decrease in absorbance at 340 nm of the NADH. Since acycloguanosine monophosphate is a much poorer substrate for the kinase than compound of Formula II monophosphate, more enzyme is used in the case of acycloguanosine monophosphate (0.28 units) than in the case of compound of Formula II monophosphate (0.0056 units).

The initial velocities obtained in the above experiment are used to compute the kinetic parameters of the two substrates which are presented in the following table. The parameters obtained in a similar experiment for deoxyguanosine monophosphate are included for comparison:

	Compound of Formula II Monophos- phate	Acyclo- guanosine monophosphate	Deoxy- guanosine monophosphate
Km (μ M)	22	316	124
V _{max} (μ g/min/mg)	7.1	0.20	17.2
V _{max} /Km	0.32	0.00065	0.14

The relative efficiency of compound of Formula II monophosphate and acycloguanosine monophosphate as substrates for the enzyme which converts them to the respective diphosphates is 0.32/0.00065 or 492 to 1.

EXAMPLE 30

Enzymatic Preparation of the Acyclic Monophosphate of Compound of Formula I

The compound of formula I (1 mg) was incubated at 37° in a mixture containing: 50 mM potassium phosphate buffer at pH 6.5; bovine serum albumin, 1 mg/ml; adenosine triphosphate, 5 mM; magnesium chloride, 5 mM; dithiothreitol, 1 mM; phosphocreatine 1 mM; creatine kinase, 12.5 units/ml; sodium fluoride, 2.5 mM; and 20 units of purified HSV 1-induced thymidine kinase, in a total volume of 0.5 ml. The progress of the reaction was monitored by high performance liquid chromatography (HPLC). When 65% of the compound of formula I had been converted to the monophosphate, the reaction was terminated. The product was purified by HPLC chromatography on a preparative anion exchange column (AX-10, Varian) and desalted by chromatography on diethylaminoethyl cellulose (DEAE) with triethylammonium carbonate pH 7.6 as the eluting solvent. Freeze-drying of the solvent from the pooled fractions containing the product yielded 500 µg of compound I monophosphate, the purity of which was confirmed by analytical HPLC.

EXAMPLE 31Treatment of Virus Infections in Cell cultures in Vitro.

5 Assays were performed in various cell culture systems to determine the minimum concentrations of the compounds of Formula I, Formula II or acycloquanosine that were effective in preventing several different kinds of virus infections.

10 a. Herpes simplex virus types 1 and 2: The compounds of Formula I, Formula II or acycloquanosine required to totally suppress the development of viral cytopathology in 50% of rabbit kidney cell monolayers infected with 10 tissue culture infectious doses
15 (TCID₅₀) of either virus are shown in the attached Table. All three compounds showed comparable activity.

20 b. Varicella-Zoster virus: Both the compound of Formula II and acycloquanosine were equally active against this herpesvirus as determined by a plaque-reduction assay using monolayers of human fetal diploid lung cells, MRC-5. The results are shown in the attached Table.

25 c. Epstein-Barr virus (EBV): Continuous treatment of EBV-infected umbilical cord cells (B lymphocytes) with 1-5 µg/ml of the compound of Formula II from the time of infection resulted in inhibition of the transformation of the normal lymphocytes into
30 continuously growing lymphoblastoid cells. By contrast, between 10 and 100 µg/ml of acycloquanosine

were required to show similar activity. The results are shown in the attached Table.

d. Cytomegalovirus: The compound of Formula II
5 was effective in suppressing cytomegalovirus plaque
formation on MRC-5 cell monolayers using 0.1 to 0.6
µg/ml. In order to obtain equivalent plaque
suppression (50%) using acycloquanosine required 2.2 -
17.7 µg/ml. The calculated average relative potency of
10 the compound of Formula II to acycloquanosine (95% CI)
was 28.6. The results are shown in the attached Table.

15

20

25

30

- 50 -

16672IA

Minimum Concentrations of Formula I, Formula II or Acycloguanosine
Active Against Herpesviruses in Cell Cultures

5	Virus	Minimum Effective Concentration (µg/ml)		
		Formula I	Formula II	Acycloguanosine
10	Herpes simplex type 1 (Strain Schooler)	1-3 ^a	1-3 ^a	1-3 ^a
	" " " (Strain S)	ND	1-3 ^a	ND
	" " " (Strain McIntyre)	ND	3 ^a	ND
	" " " (Strain McKrae)	ND	1-3 ^a	ND
	" " " 2 (Strain Curtiz)	3-6 ^a	1-3 ^a	1-3 ^a
15	Varicella-Zoster (Strain KMCC)	ND	1-2 ^b	1-2 ^b
	Epstein-Barr (B ₉₅₋₈)	ND	1-5 ^c	10-100 ^c
	Cytomegalovirus (Towne Strain)	ND	0.1-0.6 ^d	2.2-17.7 ^d

ND - Not done

a - Tube dilution assay on primary rabbit kidney cell cultures.

b - Plaque reduction assay on human MRC-5 cell monolayers.

c - Human cord blood lymphocyte transformation assay.

20 d - Plaque reduction assay on human MRC-5 cell monolayers

EXAMPLE 32Treatment of Herpes Simplex Virus Infection in Mice

Twenty gram ICR/Ha mice were injected intraperitoneally (ip) with 0.5 ml of a 10^{-5} dilution of a stock preparation of Herpes simplex virus type I (HSV-1), strain Schooler. This virus challenge infected each animal with approximately 100 LD₅₀. Starting immediately after virus infection and continuing twice daily for 4 days, each animal was injected subcutaneously in groups of 15 with: 500 µg, 125 µg or 31 µg of acycloquanosine; 500 µg, 125 µg, or 31 µg of the compound of formula I; 500 µg, 125 µg, or 31 µg of the compound of formula II; or placebo (physiological saline, pH 11.5). The placebo group was composed of 45 animals. All compounds were solubilized in physiological saline, pH 11.5.

The mice were observed daily for 15 days at the same time each day and the day of death was recorded for each animal.

Statistical analyses (reference: Liddel, F.D.K., 1978, Evaluation of Survival in Challenge Experiments, Microbiol. Rev., 42: 237-249) were performed on survival times transformed by the negative exponential transformation:

$$f(t) = 1 - (0.1)^{t/T}$$

where t = number of days an animal survived

T = duration of trial (15 days)

- 52 -

16672IA

A continuity correction was used to account for daily observation:

$$f_c(t) = 1/2 [f(t) + f(t-1)]$$

Within each group, mice surviving through the trial period were assigned equally values of 0.9 and 1.0 to adjust for termination of the trial.

Average survival time per group was calculated from average corrected transformed survival times $[f_c(t)]$ as follows:

$$t_{avg} = [T/\log(0.1)] \cdot [\log(1-f_c(t))]$$

The summarized results are shown in the following Table:

15	Chemical Agent	Animal Treatment		Percent Survival*	Avg. Survival Time (Days)
		µg/dose	mg/kg/day		
20	Acycloguanosine	500	50	0	7.7
		125	12.5	6	6.2**
		31	3.1	6	6.4**
25	Compound of Formula I	500	50	60	11.8
		125	12.5	26	9.0
		31	3.1	0	6.3**
30	Compound of Formula II	500	50	100	14.1
		125	12.5	73	14.1
		31	3.1	53	12.5
30	Placebo	0.1 ml	-	6	6.2

* determined at 15 days

** values not statistically different from that of placebo treated animals ($P > 0.05$)

EXAMPLE 33Treatment of Herpes Simplex Virus Infection in Mice

The experiment described in Example 32 was repeated, except that each animal was injected twice daily subcutaneously in groups of 15 with: 1000 μ g, 500 μ g or 125 μ g of acycloguanosine; 500 μ g, 125 μ g or 31 μ g of the compound of Formula I; 500 μ g, 125 μ g, 31 μ g, 8 μ g or 2 μ g of the compound of Formula II; or placebo. The 1000 μ g dose acycloguanosine treatment group and the 500 μ g dose treatment group of the compound of Formula II were composed of 10 animals each. The summarized results are shown in the following Table:

15

20

25

30

- 54 -

16672IA

	Chemical Agent	Animal Treatment		Percent Survival*	Avg. Survival Time (Days)
		µg/dose	mg/kg/day		
5	Acycloguanosine	1000	100	10	7.8
		500	50	0	7.8
		125	12.5	6	7.0**
10	Compound of Formula I	500	50	36	10.5
		125	12.5	33	9.8
		31	3.1	6	7.2**
	Compound of -	500	50	100	19.5
15	Formula II	125	12.5	93	17.2
		31	3.1	46	11.8
		8	0.8	40	9.8
		2	0.2	26	9.0
20	Placebo	0.1 ml	-	0	6.3

* determined at 15 days

** values not statistically different from that of placebo treated animals ($P > 0.05$)

30

Using combined results from Examples 32 and 33, the calculated average relative potencies of the compound of Formula I and the compound of Formula II to acycloguanosine (95% CI) were 9.2 and 287.0, respectively.

EXAMPLE 34

The following is a summary of in vitro and in vivo antiviral activities of potassium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate against Herpes simplex virus Type 1 (HSV1) and Type 2 (HSV2).

In Vitro Assays:

Method: Confluent monolayers of primary rabbit kidney cell cultures were refed with maintenance medium containing serial dilutions of the test compounds and incubated overnight at 37°. At each dilution, four cultures were challenged with approximately 10 TCID₅₀ HSV1, four cultures were challenged with approximately 10 TCID₅₀ HSV2 and two cultures were left as toxicity controls. Cultures were reincubated at 37° and observed for viral induced cytopathology at days 5 and 7.

Results:

Compound	Min. Effective Dose (µg/ml)		
	Against		
	<u>HSV1</u>	<u>HSV2</u>	<u>Toxicity</u>
Potassium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate	12.5 25	50 100	Not tox. at 100

In Vivo Assays:

Method: Twenty gram ICR/Ha mice were infected with approximately 100 lethal doses ($100LD_{50}$) of HSV1

- 5 (Strain Schooler) by the intraperitoneal route. Groups of 10 infected animals were treated twice daily for four days starting immediately after infection by subcutaneous injection at final daily doses of 50, 12.5, 3.1, 0.8, 0.2, 0.05 and 0.0125 mg/kg of potassium
- 10 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate. The mice were observed daily for 15 days at the same time each day and the day of death recorded for each animal. Average survival times (days) and percent survival at 15 days are shown in the
- 15 accompanying table.

20

25

30

- 57 -

16672IA

Compound	Animal		Ave. Survival	
	Treatment	Percent Survival	Time (days)	
	mg/kg/day	Expt. 1	Expt. 2	Expt. 1 Expt. 2
5 Potassium 9-(1,3-dihydroxy-2-propoxymethyl) - guanine cyclic monophosphate	50	100	ND	19.5 ND
	12.5	100	60	19.5 15.0
	3.1	20	50	10.7* 11.5
	0.8	40	0	10.5* 7.4*
10	0.2	70	30	13.5 8.3*
	0.05	ND	0	ND 6.0*
	0.0125	ND	10	ND 6.3*
Placebo	0.1 ml	20	10	7.8 6.4

15

* - Values not statistically different from that of placebo treated animals (P 0.05) calculated for survival times.

20

Conclusion: Potassium 9-(1,3-dihydroxy-2-propoxymethyl)guanine cyclic monophosphate has demonstrated significant antiviral activity against Herpes simplex viruses in vitro and in vivo.

25

30

Example 35

Treatment of Herpes Simplex Virus Infection in Mice:
Intraperitoneal Herpes Simplex Type 1 Infection, Oral
5 Treatment

ICR/Ha mice were infected as described in
Example 32. Groups of 10 infected animals were treated
twice daily for 7 days by oral gavage at final daily
doses of 100, 50, 12.5, 3.1 or 0.8 mg/kg of
10 acycloguanosine, or 50, 12.5, 3.1, 0.8 or 0.2 mg/kg of
the compound of Formula II starting immediately after
infection. In addition, two groups of five uninfected
animals were treated with either acycloguanosine or the
compound of Formula II twice daily for 7 days by oral
15 gavage at final daily doses of 50 mg/kg. These animals
served as toxicity controls. The summarized results
are shown in the following Table:

20

25

30

- 59 -

16672IA

Oral Treatment of
Intraperitoneal Herpes Simplex Virus
Type I Infection of Mice

5	Chemical Agent	<u>Animal Treatment</u>		Percent Survival*	Avg. Survival Time (days)
		<u>ug/dose</u>	<u>mg/kg/day</u>		
10	Acycloguanosine	1000	100	60	11.4
		500	50	20	8.2
		125	12.5	0	6.6**
		31	3.1	0	6.3**
15	The Compound of Formula II	500	50	100	16.9
		125	12.5	80	13.9
		31	3.1	50	11.7
		8	0.8	20	8.5
		2	0.2	0	6.8**
20	Placebo	0.1		10	4.3

* determined at 13 days

25 ** values not statistically different from that of placebo treated animals ($P > 0.05$). Calculated for survival times only.

30

Treatment with the compound of Formula II resulted in statistically significant extension of survival time compared to placebo-treated animals at 50, 12.5, 3.1 and 0.8 mg/kg daily doses.

5 Acycloguanosine treatment resulted in statistically significant extension of survival time compared to placebo-treated animals only at 100 and 50 mg/kg daily doses.

10 All animals treated with 50 mg/kg of the compound of Formula II survived the test; survival of the 50 and 12.5 mg/kg treatment groups was statistically significantly longer than the placebo-treated group. By contrast, none of the acycloguanosine-treated groups showed enhanced
15 survival.

The relative potency of the compound of Formula II to acycloguanosine was 50.3, which was statistically significant.

20 There was no evidence of overt toxicity in either the acycloguanosine or the compound of Formula II treatment groups as measured by final weight of test animals.

Example 36

25

Treatment of Herpes Simplex Virus Infection in Mice:
Vaginal Herpes Simplex Virus Type 2 Infection, Oral Treatment.

30 Thirty gram ICR/Ha female mice were infected with more than 10 LD₅₀ of Herpes simplex virus type 2 (Strain Curtis) by the intravaginal route. Groups

of 10 animals were treated twice daily for ten days by oral gavage using acycloguanosine or the compound of Formula II at final daily doses of 50, 12.5, 3.1, 0.8 or 0.2 mg/kg starting immediately following infection. The average number of days to infection and the average days of survival were determined for each group and compared to an infected, placebo-treated group. The summarized results are shown in the following Table.

10

15

20

25

30

- 62 -

16672IA

ORAL TREATMENT OF VAGINAL HERPES SIMPLEX VIRUS TYPE II
INFECTION OF MICE

	Chemical Agent	Animal Treatment µg/dose mg/kg/day	Percent Survival*	Avg. Survival Time (days)
5		750	50	60
		188	12.5	40
	Acycloquanosine	47	3.1	20
		12	0.8	10
		3	0.2	0
10	The Compound of Formula II	750	50	100
		188	12.5	100
		47	3.1	75
		12	0.8	40
		3	0.2	30
15	Placebo	0.1 ml	-	0

* determined at 19 days

** values not statistically different from that of placebo treated animals ($P > 0.05$); Calculated for survival times only

All animals treated with the compound of Formula II at 50 mg or 12.5 mg/kg survived the test; survival rates of the 50, 12.5 and 3.1 mg/kg the compound of Formula II treatment groups were statistically significantly increased compared to the placebo-treated group. By contrast, only the 50 mg/kg acycloguanosine treatment group showed statistically significant enhanced survival.

The compound of Formula II at 50, 12.5, 3.1 and 0.8 mg/kg resulted in a statistically significant increase in survival time compared to placebo-treated infected animals. Acycloguanosine at 50 and 12.5 mg/kg was similarly effective.

The relative potency of the compound of Formula II to acycloguanosine as measured by survival was 28.1, which was statistically significant.

All animals treated with the compound of Formula II at 50 mg/kg remained free of signs of herpetic infection for the duration of the test. The compound of Formula II and acycloguanosine at both 50 mg/kg and 12.5 mg/kg resulted in statistically significant increases in the number of days to infection (development of vaginal lesions and/or paralysis) compared to placebo-treated animals.

The relative potency of the compound of Formula II to acycloguanosine as measured by time to infection was 4.14, which was statistically significant.

EXAMPLE 37

Treatment of Herpes Simplex Virus Infection in Mice:
Orofacial Herpes simplex Virus Type 1 Infection, Oral
Treatment.

5 Twenty gram HRS (hairless) mice were infected
on the abraded orofacial area with Herpes simplex virus
type 1 (Strain S). Groups each composed of 10 infected
animals were treated by oral gavage twice daily for 7
days starting 3 hours after infection using final daily
10 doses of 50, 12.5, 3.1 and 0.8 mg/kg for
acycloquanosine and 50, 12.5, 3.1, 0.8 and 0.2 mg/kg
for the compound of Formula II. At 7 days after
initiation of infection, the extent of lesion
development in the orofacial area was measured on a
15 scale of 0 (no lesions) to 4 (massive lesions over the
entire snout). Lesion incidence and average lesion
scores are shown in the accompanying Table and in
Figure 2.

 The compound of Formula II treatment resulted
20 in statistically significant protection at all
concentrations used compared to placebo-treated
infected animals when measured in terms of extent of
lesion development. Acycloguanosine treatment resulted
in statistically significant protection only at 50 and
25 12.5 mg/kg doses.

 The compound of Formula II treatment resulted
in statistically significant protection at 50 and 12.5
mg/kg doses compared to the incidence in placebo-
treated infected animals when measured in terms of
30

incidence of lesions. By contrast, acycloguanosine treatment resulted in statistically significant protection only at 50 mg/kg.

5 The relative potency of the compound of Formula II to acycloguanosine was 6.9, which was statistically significant.

10

15

20

25

30

	Chemical Agent	<u>Animal Treatment</u>		<u>Lesion Incidence</u>		Lesion Severity ^a
		<u>ug/dose</u>	<u>mg/kg/day</u>	<u>Total</u>	<u>(%)</u>	
5	Acycloguanosine	500	50	1/7	(14)	0.14
		125	12.5	6/6	(100)**	2.67
		31	3.1	6/6	(100)**	3.25**
		8	0.8	7/8	(88)**	3.11**
10	The Compound of Formula II	500	50	1/10	(10)	0.05
		125	12.5	2/10	(20)	0.45
		31	3.1	6/9	(67)**	1.00
		8	0.8	7/7	(100)**	2.93
		2	0.2	7/7	(100)**	2.93
	Placebo	0.1 ml	-	10/10	(100)	3.95

15 ^a Lesion severity was measured on a scale of 0 (no lesions) to 4 (massive lesions over the entire orofacial area), with the average lesion score presented in this Table.

** Values not statistically different from that of placebo treated animals ($P > 0.05$).

20 Lesion incidence and severity were determined seven days following orofacial infection.

EXAMPLE 38

Treatment of Herpes Simplex Virus Infection in Mice:
Orofacial Herpes simplex Virus Type 1 Infection,
Therapeutic Oral Treatment

5 Twenty gram HRS (hairless) mice were infected
on the abraded orofacial area with Herpes simplex virus
type 1 (Strain S).

 a. Groups of 10 infected animals were
treated twice daily by oral gavage for up to 7 days
10 with the compound of Formula II at 12.5
mg/kg/day, starting 3, 8, 12, 24, 48, 72, or 96 hours
after infection.

 b. In a second experiment, the therapeutic
efficacy of acycloguanosine was evaluated in a similar
15 manner. Groups of 10 infected animals were treated
twice daily by oral gavage for up to 7 days with
acycloguanosine at 12.5 mg/kg/day, starting at 3, 8,
12, 24, 48, 72, or 96 hours after infection.

 At 7 days after initiation of infection, the
20 extent of lesion development in the orofacial area was
measured on a scale of 0 (no lesions) to 4 (massive
lesions over the entire snout). Average lesion scores
are shown in the accompanying Table.

 Infected mice receiving the compound of
25 Formula II starting as late as 72 hours after infection
with HSV-1 showed statistically significant lower
lesion scores than mice receiving placebo. By
contrast, for acycloquanosine treatment, only mice
receiving treatment starting 3 hours after infection
30 were statistically different in lesion score than the
placebo group.

In addition, infected mice receiving the compound of Formula II starting at 8, 12 and 24 hours after infection had a statistically significant lower incidence of lesion development than mice receiving placebo. None of the acycloguanosine treated groups had a significantly lower incidence of lesions than the respective placebo treated animals.

10

15

20

25

30

**Therapeutic Oral Treatment of Orofacial Herpes Simplex Virus Type I
Infection of Mice**

5	Chemical Agent	Start of Oral ^a		Lesion Incidence		Lesion Severity ^b
		Treatment (Hours post infection)		Total	(%)	
10	Acycloguanosine 12.5 mg/kg/day	3		10/10	(100)**	2.80
		8		10/10	(100)**	2.95**
		12		9/10	(90)**	3.30**
		24		9/10	(90)**	2.85**
		48		8/10	(80)**	2.85**
		72		9/10	(90)**	3.60**
		96		7/7	(100)**	4.00**
	Placebo	3		9/9	(100)	3.35
10	The Compound of Formula II 12.5 mg/kg/day	3		6/10	(60)**	1.30
		8		3/10	(30)	0.55
		12		5/10	(50)	0.55
		24		4/10	(40)	0.40
		48		9/10	(90)**	1.50
		72		8/10	(80)**	2.55
		96		10/10	(100)**	3.85**
	Placebo	3		10/10	(100)	4.00

^a Oral treatment was started at the indicated times after initiation of infection and continued with dosing twice each day for seven days.

25 Lesion incidence and severity were determined seven days following orofacial infection.

^b Lesion severity was measured on a scale of 0 (no lesions) to 4 (massive lesions over the entire orofacial area), with the average lesion score presented in this table.

30 ** Values not statistically different from that of placebo treated animals ($P > 0.05$).

Methods of Preparing Phosphate Derivatives of
Compounds of Formula I and II.


5 The mono- and polyphosphate derivatives of
compounds of formulas I and II can be prepared chemi-
cally by reacting a compound of formula I or II with
a phosphorylating agent such as phosphoryl chloride
in a suitable aprotic solvent such as triethyl phos-
phate and treating the resulting intermediate with
10 water or base. The major product of this reaction is
the cyclic phosphate of compound I or II, but acyclic
mono- and di-phosphates are also produced. The pro-
duct ratios can be varied by changes in the amounts
of the reactants or the length and temperature of
treatment.

15 It is also convenient to isolate the phosphory-
lated intermediate by precipitation with a nonpolar
hydrocarbon solvent and quench with an alcohol. The
product of this reaction can be either an alkyl
phosphotriester or an alkyl phosphodiester de-
20 rivative depending upon whether a basic aqueous
treatment is employed or not.

The phosphorylated derivatives of the compounds
of formulas I and II [namely the mono-, linear di-
(pyrophosphate), or linear tri-phosphate] can also
25 be prepared enzymatically by treatment of the com-
pound of formulas I or II with HSVI thymidine kinase
(to produce the monophosphate), additionally with
guanosine monophosphate kinase (to produce the pyro-
phosphate), and additionally with 3-phosphoglycerate
30 kinase (to prepare the triphosphate).


WHAT IS CLAIMED IS:

1. A compound of the formula:



15

wherein R^1 and R^2 are independently H,



25

R^3 is H, alkyl of 1-20 carbon atoms which may be straight chain or branched, saturated or mono- or polyunsaturated, aryl, substituted aryl, heterocyclyl, aralkyl, alkoxyalkyl or aryloxyalkyl,


R^4 and R^5 are independently H, a pharmaceutically acceptable cation, alkyl of 1-8 carbon atoms which may be straight chain or branched, aryl, aralkyl,

phosphate or pyrophosphate, and R^8 is H or $\text{R}^3\text{-C(=O)-}$.

30

2. A compound of Claim 1 wherein each of R^1 , R^2 and R^8 is H.

7. A method of preparing a compound of Claim 1 wherein R^1 , R^2 and R^8 are each H which comprises deacylating a compound of the formula



10 wherein R^6 is $\text{CH}_2\text{O}\overset{\text{O}}{\parallel}\text{CR}^3$ and R^7 is $\text{CH}_2\text{O}\overset{\text{O}}{\parallel}\text{CR}^3$

or wherein R^6 is $\text{CH}(\text{O}\overset{\text{O}}{\parallel}\text{CR}^3)\text{CH}_2\text{O}\overset{\text{O}}{\parallel}\text{CR}^3$ and R^7 is H,

and R^8 is H or $\text{H}\overset{\text{O}}{\parallel}\text{CR}^3$ as defined in Claim 1.

8. A method of preparing a compound of Claim 6 which comprises reacting a compound of formula I or II of Claim 1 wherein R^1 , R^2 and R^8 are each H with an acylating compound of the formula $\text{R}\overset{\text{O}}{\parallel}\text{CX}$ wherein X is a carboxyl activating group whereby a monoacylated derivative is formed when the reaction is allowed to proceed until 1 equivalent of the acylating compound is reacted with the compound of formula I or II, or whereby a diacylated derivative is formed when the reaction is allowed to proceed until 2 equivalents of the acylating compound are reacted with the compound of formula I or II or whereby a triacylated derivative is formed when 3 equivalents of the acylating agent are reacted with the compound of formula I or II.

9. A method according to Claim 8 wherein the carboxyl activating group is halide, acyloxy, 1-benzotriazolyloxy, N-succinimidylloxy or 1,3-disubstituted isoureido.

5 10. A method of preparing a compound of Claim

1 wherein R^1 and R^2 are H, or $\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OR}^4 \\ | \\ \text{OR}^5 \end{array}$, or OR^1

10 and OR^2 together are $\begin{array}{c} \text{O} \\ \parallel \\ -\text{O}-\text{P}-\text{OR}^4 \\ | \\ -\text{O} \end{array}$ and R^8 is H, which

15 comprises reacting a compound of formula I or II of Claim 1 wherein R^1 , R^2 and R^8 are each H with a phosphorylating agent and treating the resultant intermediate with water or an alkanol of 1-8 carbon atoms and isolating at least one of the resultant acyclic or cyclic phosphate derivatives.

20 11. A method according to Claim 10 wherein the phosphorylating agent is POX_3 wherein X is halogen.

25 12. A method of preparing a compound of Claim 1 wherein one of R_1 and R_2 is H and the other is

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OR}^4 \\ | \\ \text{OR}^5 \end{array}$ and R^8 is H and R^4 is as defined in Claim 1

30 and R^5 is either H or a pharmaceutically acceptable cation which comprises reacting a compound of formula I or II, in which OR^1 and OR^2 together are

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{O}-\text{P}-\text{OR}^4 \\ | \\ -\text{O} \end{array}$ with an aqueous alkali metal hydroxide.

13. A method of preparing a monophosphate derivative of a compound of formula I or II of Claim 1 wherein R^1 , R^2 and R^8 are each H which comprises incubating said compound of formula I or II in the presence of HSV1 thymidine kinase and adenosine triphosphate.

14. A method for preparing a pyrophosphate derivative of a compound of formula I or II of Claim 1 wherein R^1 , R^2 and R^8 are each H which comprises incubating said compound of formula I or II in the presence of HSV1 thymidine kinase, adenosine triphosphate and guanosine monophosphate kinase.

15. A method for preparing a linear triphosphate derivative of a compound of formula I or II of Claim 1 wherein R^1 , R^2 and R^8 are each H which comprises incubating said compound of formula I or II in the presence of HSV1 thymidine kinase, adenosine triphosphate, guanosine monophosphate kinase and extract of HSV1-infected cells.

16. A method for preparing a linear triphosphate derivative of a compound of formula I or II of Claim 1 wherein R^1 , R^2 and R^8 are each H which comprises incubating a compound of formula I or

II wherein one of R^1 or R^2 is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OR}^4 \\ | \\ \text{OR}^5 \end{array}$ and the

other is H and R^4 is phosphate, and R^8 is H, with 3'-phosphoglycerate kinase, 3-phosphoglycerate dehydrogenase and 3-phosphoglycerate dehydrogenase.

17. A composition for treating a herpes virus infection in a mammalian or avian species, which contains a compound of Claim 1 in a quantity effective to impart an anti-herpes virus effect.

5 18. A composition according to Claim 17 for administering the compound at from about 0.01 to about 200 mg/kg.

 19. A composition according to Claim 17 for topically administering the compound at a dosage level of from
10 about 0.1 % to about 5 % by weight.

 20. A composition according to Claim 19 wherein the dosage level is from about 0.25 % to about 3 % by weight.

 21. A composition according to Claim 17 for orally
15 or parenterally administering the compound, at a dosage level of from about 0.8 to about 100 mg/kg.

 22. A composition according to Claim 21 wherein the dosage level is from about 5 to about 50 mg/kg.

1/2




FIG. 1

2/2

ORAL TREATMENT OF MICE HAVING HSV-1 OROPACIAL INFECTION USING COMPOUND
OF FORMULA II OR ACYCLOGUANOSINE
S= SIGNIFICANT PROTECTION ($P < 0.05$)




FIG. 2



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)